Related Experiment Video
Updated: Jan 14, 2026
![[DPEPhosbcpCu]PF6: A General and Broadly Applicable Copper-Based Photoredox Catalyst](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59739.jpg&w=3840&q=50)
[DPEPhosbcpCu]PF6: A General and Broadly Applicable Copper-Based Photoredox Catalyst
Published on: May 21, 2019
Bidirectionally H2O2-suppliable and antioxidant-consumable copper peroxide nanoparticles for photochemodynamic
Yanan Zhao1, Ting Li1, Yao Yao2
1Engineering Research Center of RNA Medicine and Cell Therapy Technology, Ministry of Education, Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, and College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
Abstract:
Reactive oxygen species (ROS)-based antitumor compounds show great promise in cancer treatments such as chemodynamic therapy (CDT) and photodynamic therapy (PDT), but are severely restricted by both endogenous antioxidants and hydrogen peroxide (H2O2). Here, we synthesize bidirectionally H2O2-suppliable and antioxidant-consumable copper peroxide (CuO2) nanoparticles for CDT/PDT-synergized immunotherapy against aggressive triple-negative breast cancers (TNBCs). The CuO2 nanoparticles are established to afford pH-responsive decomposition into H2O2 and Cu2+, followed by the reduction into Cu+ by glutathione and subsequent catalysis reaction of H2O2 into highly reactive ·OH, thus yielding CDT-mediated cell injury. Meanwhile, the glutathione consumption from the nanoparticles attenuates their ROS scavenging to promote singlet oxygen generation of co-assembled indocyanine green upon light exposure, thereby amplifying PDT-based cell damage. Moreover, the dully enhanced CDT/PDT damages of the nanoparticles provoke potent immunogenic cell death that further synergizes with immune checkpoint inhibitor via relieving indoleamine 2,3-dioxygenase 1-mediated immunosuppression, thus amplifying immunotherapeutic efficacy against primary, distant and metastatic TNBCs. This work provides valuable insights into nanomedicines for synergistic cancer therapy.

